Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. METHODS: We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. RESULTS: TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination).TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient's care, while reducing the potential for bias. CONCLUSIONS: When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIAL REGISTRATION TRIGGER: ISRCTN85757829. Registered 26 July 2012.TAPPS: ISRCTN47845793. Registered 28 May 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Where outcome assessment is feasible, blinding assessors to intervention status may reduce information bias (17).”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 1×
“If patients, clinicians, or assessors are aware of treatment assignments, this may influence reporting or measurement of the outcome and introduce bias [1].”
BackgroundSchulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“It is therefore recommended that trials be blinded (or masked) as far as possible to limit bias [2,3].”
BackgroundWood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538 · cited 2×
“However, evidence suggests that treatment effect estimates may be exaggerated for subjective outcomes when outcome assessors are not blinded [6-13].”
BackgroundTutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440 · cited 1×
“This is known as a competing-risk [19], and could potentially lead to bias, or a reduction in power.”
BackgroundTransfusion Strategies for Acute Upper Gastrointestinal Bleeding
Villanueva, C., Colomo, A., Bosch, A., Concepción, M., Hernandez-Gea, V., Aracil, C., Graupera, I., Poca, M., Alvarez-Urturi, C., Gordillo, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211801 · Cited by 1,735 · cited 1×
“Similarly, previous trials in patients with AUGIB have often used a fall in the patient’s Hb level as a surrogate for further bleeding (along with other less objective measures, as described earlier) [21].”
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., et al. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.011 · Cited by 1,389
Savović, J., Jones, H. E., Altman, D. G., Harris, R. J., Jüni, P., Pildal, J., Als-Nielsen, B., Balk, E. M., Gluud, C., Gluud, L. L., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-6-201209180-00537 · Cited by 1,049 · cited 1×
“However, evidence suggests that treatment effect estimates may be exaggerated for subjective outcomes when outcome assessors are not blinded [6-13].”
BackgroundBlinding in randomised trials: hiding who got what
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07816-9 · Cited by 952
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion
Dresler, C. M., Olak, J., Herndon, J. E., Richards, W. G., Scalzetti, E., Fleishman, S. B., Kernstine, K. H., Demmy, T., Jablons, D. M., Kohman, L., et al. (2005) · Chest · doi:10.1378/chest.127.3.909 · Cited by 578 · cited 1×
“For example, previous trials in patients with malignant pleural effusion have often used the amount of fluid on a patient’s chest x-ray as a surrogate for pleurodesis failure [20].”
BackgroundLinde, K., Witt, C. M., Streng, A., Weidenhammer, W., Wagenpfeil, S., Brinkhaus, B., Willich, S. N., & Melchart, D. (2007) · Pain · doi:10.1016/j.pain.2006.12.006 · Cited by 551
Cited by
Yoon, S. M., Ryoo, B.-Y., Lee, S. J., Kim, J. H., Shin, J. H., An, J. H., Lee, H. C., & Lim, Y.-S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5847 · Cited by 446
Juch, J. N. S., Maas, E. T., Ostelo, R. W. J. G., Groeneweg, J. G., Kallewaard, J.-W., Koes, B. W., Verhagen, A. P., van Dongen, J. M., Huygen, F. J. P. M., & van Tulder, M. W. (2017) · JAMA · doi:10.1001/jama.2017.7918 · Cited by 261
Orhurhu, V., Orhurhu, M. S., Bhatia, A., & Cohen, S. P. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004185 · Cited by 179
de-Madaria, E., Herrera-Marante, I., González-Camacho, V., Bonjoch, L., Quesada-Vázquez, N., Almenta-Saavedra, I., Miralles-Maciá, C., Acevedo-Piedra, N. G., Roger-Ibáñez, M., Sánchez-Marin, C., et al. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640617707864 · Cited by 175
“However, randomization alone does not preclude the possibility of systematic differences: If patients, clinicians, or assessors are aware of treatment assignments, this may influence reporting or measurement of the outcome and introduce bias.(5,6) Furthermore, the study had four arms of treatment.”
The effects of dairy and dairy derivatives on the gut microbiota: a systematic literature review
Aslam, H., Marx, W., Rocks, T., Loughman, A., Chandrasekaran, V., Ruusunen, A., Dawson, S. L., West, M., Mullarkey, E., Pasco, J. A., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1799533 · Cited by 170
“The unblinded trials are prone to bias estimates of treatment effects.(52) However, in RCTs with biological outcomes this is less of an issue.”
Background
Metadata
- Authors
- Kahan, B. C., Cro, S., Doré, C. J., Bratton, D. J., Rehal, S., Maskell, N. A., Rahman, N., & Jairath, V.
- Affiliations
- Queen Mary University of London (GB)
- MRC Clinical Trials Unit at UCL (GB)
- University of Bristol (GB)
- University of Oxford (GB)
- Corresponding author
- Kahan, Brennan C
- ORCID
- Venue
- Trials
- Published
- 2014-11-21
- Volume
- 15
- Issue
- 1
- Pages
- 456-456
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC4247637
- OpenAlex
- W2169252265
- Cited by
- 123
- References
- 23
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 11 · 2023: 20 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 10 · 2018: 5 · 2017: 12 · 2016: 4 · 2015: 3
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Trials (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (CL-2013-13-008)
- Medical Research Council (MC_EX_G0800814)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- bias mitigation, adjudication committee
- MeSH terms
- Drainage, Gastrointestinal Hemorrhage, Humans, Recurrence, Referral and Consultation, Research Design, Time Factors, Bias, Pleural Effusion, Malignant, Treatment Outcome, Erythrocyte Transfusion, Pleurodesis, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. https://app.cochat.ai/papers/10.1186/1745-6215-15-456
- The paper
- Kahan, B. C., Cro, S., Doré, C. J., Bratton, D. J., Rehal, S., Maskell, N. A., Rahman, N., & Jairath, V. (2014). Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. https://doi.org/10.1186/1745-6215-15-456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.